The Lancet Commission on women, power, and cancer: Patient Stories

Gender inequity in ovarian cancer research in resource limited settings

Synthetic biology and precision medicine in blood and gynaecological cancers

Low-dose olanzapine after highly emetogenic chemotherapy can be the new standard of care for solid tumours

First-line chemotherapy with atezolizumab and bevacizumab significantly improves survival for R/M cervical cancer

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer

Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer

Gynaecological Cancers

Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC

Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer

Durvalumab addition to chemo shows endometrial cancer benefit

Part 6: Which different PARP inhibitors are available